Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Psoriasis drug could slow type 1 diabetes progression in new trial

NCT ID NCT04589325

First seen Apr 30, 2026 · Last updated Jun 18, 2026 · Updated 10 times

Summary

This study tests whether ixekizumab, a drug already approved for psoriasis, can help people newly diagnosed with type 1 diabetes keep making some of their own insulin. About 127 adults aged 18-45 who were diagnosed within the last 100 days will receive either the drug or a placebo for 52 weeks. The main goal is to see if the drug slows the loss of insulin-producing cells, potentially reducing the amount of insulin injections needed.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TYPE1 DIABETES MELLITUS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Centrum för Diabetes,

    Stockholm, Sweden

  • Falu Lasarett

    Falun, Sweden

  • Karlstad lasarett

    Karlstad, Sweden

  • Kristianstad Hospital

    Kristianstad, Sweden

  • Linköping University Hospital

    Linköping, Sweden

  • Lund University Hospital

    Lund, Sweden

  • Länssjukhuset Ryhov

    Jönköping, Sweden

  • NU-Hospital Group

    Uddevalla, Sweden

  • Sahlgrenska University Hospital, Sahlgrenska

    Gothenburg, Sweden

  • Sahlgrenska University Hospital, Östra Hospital

    Gothenburg, Sweden

  • Skaraborgs sjukhus

    Skövde, Sweden

  • Södersjukhuset Hospital

    Stockholm, Sweden

  • Södra Älvsborg Hospital

    Borås, Sweden

  • Uppsala Academic Hospital

    Uppsala, Sweden

  • Varbergs sjukhus

    Varberg, Sweden

  • Vrinnevi Hospital

    Norrköping, Sweden

  • Örebro University Hospital

    Örebro, Sweden

Conditions

The condition(s) this trial relates to.

type 1 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.